Janus Research Fund (JAMRX)

Large-Cap Growth Utilizing Our Analysts' Best Ideas



Inception Date5/3/1993
NAV (As of 9/30/16)$42.67
Total Net Assets (As of 8/31/16)$4.56B
Annual Expense Ratio
(As of fiscal year end 9/30/15)
GROSS 1.00%
NET 1.00%

Performance (As of 6/30/16)
1 Year-1.05%
3 Year12.40%
5 Year11.18%
10 Year9.03%
Morningstar (As of 8/31/16)
CategoryLarge Growth
Overall Rating™
(Based on risk-adjusted returns)

View All Ratings

1470 Funds Rated
Style Box

Returns quoted are past performance and do not guarantee future results; current performance may be lower or higher. Investment returns and principal value will vary; there may be a gain or loss when shares are sold. For the most recent month-end performance click here.

Returns greater than one year are annualized.

Quarterly Commentary - Q2 2016


U.S. stocks traded narrowly for much of the period, but encountered volatility in the wake of the UK’s Brexit referendum.

The Fund outperformed its benchmark, with our selection of technology and health care stocks aiding relative results.

We expect early-summer volatility to continue, but believe opportunities exist for active investors to gain attractive entry points to compelling long-term growth themes.